Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Indivior
Biotech
Private equity firms take over bluebird's nest—Chutes & Ladders
Private equity firms take over bluebird’s nest. Novartis vet vaults to FoRx. Indivior IDs next CEO.
Darren Incorvaia
,
Zoey Becker
Feb 28, 2025 8:30am
Aelis' cannabis use drug flops, Indivior rethinks $100M option
Sep 4, 2024 5:04am
Addex stock rises after Indivior offers up to $300M for compound
Aug 27, 2024 10:50am
Click, Indivior to make digital therapeutics for addiction
Sep 8, 2023 1:13pm
C4X sells substance disorder drug rights to Indivior for $20M
Aug 1, 2023 7:49am
Indivior enters cannabis use disorder field in $30M Aelis deal
Jun 8, 2021 10:35am
